I have written the requested concise biological interpretation to your agent workdir.

File
- /home/erwinpi/pantheon-agents/examples/gene_panel_selection/cases/gene_panel_selection_immune/workdir/biologist/biologist_interpretation.md

What’s included
- Interprets the 1000-gene immune-oncology panel using the annotated CSV and README.
- Highlights:
  - T/NK coverage: naive/central memory (CCR7, IL7R, TCF7), cytotoxic effectors (PRF1, GZMB, GNLY, NKG7), and exhaustion/activation continuum (TOX, CTLA4, LAG3, TIGIT, HAVCR2, ICOS); NK receptors (KLRD1; KLRC1/2/3).
  - Myeloid diversity: classical/non-classical monocytes (LST1, S100A8/A9, FCGR3A, CD14), macrophage/TAM programs (CSF1R, APOE, TREM2, CD163, MARCO, VSIG4), and DC features (ITGAX, IRF8, LAMP3, CLEC7A, FLT3LG).
  - B/plasma maturation: B-lineage (MS4A1, CD19, CD79A/B, CD74, BLNK, PAX5, POU2AF1, BANK1) and plasma differentiation (XBP1, MZB1, JCHAIN, SDC1, IGKC/IGLC2).
  - Stromal/tumor segmentation: epithelial/tumor (EPCAM, MUC1, KRTs, TACSTD2), fibroblast/pericyte/CAF (COL1/6, DCN, LUM, FAP, PDGFRA/B, TAGLN, ACTA2, SPARC; MMP2/9, LOX; integrins/adhesion), endothelium (VWF, PECAM1, PLVAP, FLT1, KDR, SELE).
  - Cytokine/chemokine axes and L–R coverage: CXCL9/10/13; CCL2/17/19/20/21; CCR1/2/5/6/7; CXCR3/4/5/6; CX3CR1; CSF1–CSF1R; TGFβ/TGFBR1/2; NOTCH ligands/receptors; VEGF/PDGF receptor axes; IL2/IL2R, IL10/IL10R, IL6, IL12A/B, IL21, IL4; IFNG.
  - Antigen presentation breadth: MHC-II (CIITA, CD74, HLA-DMA/DMB, HLA-DQA2, HLA-DRB5); MHC-I processing/non-classical (ERAP1, PSMB10, HLA-E) supported by robust ISGs (IFITM1/2/3, IFIT1-3, ISG15, MX1/2, OAS1-3, OASL, GBP5) and JAK–STAT genes.
  - Tumor-intrinsic signaling: RTK–RAS–MAPK (EGFR, ERBB2/3/4, MET, FGFR1–3, KRAS/NRAS/BRAF, MAPK1/3, MAP2K1/2); PI3K–AKT–mTOR (PIK3CA/CB/CD, AKT1/2, MTOR, RPTOR/RICTOR, TSC1/2); JAK–STAT (JAK1/2/3, TYK2, STAT1–6); TGFβ/WNT/NOTCH/Hedgehog modules; NF-κB/Hippo; DNA repair/cell cycle; EMT/hypoxia/metabolism.
- Performance references to figures:
  - UMAP comparisons: preserves global topology and major lineage/state separation (distance correlation ~0.70 to full-transcriptome).
  - ARI vs size: strong performance at 300–1000 genes (peak ~0.37 near 500; ~0.36 at 1000), competitive with DE/RandomForest.
  - UpSet: Final panel largely overlaps multi-method consensus, with strong intersections versus RandomForest and scGeneFit.
- Limitations noted:
  - Very fine DC subdivision (cDC1 vs cDC2 vs pDC) and rare ILCs may be under-resolved.
  - The most granular antigen-processing differences (e.g., specific TAP/chaperone variants) may be muted.

Citations
- Embedded concise references (Nature, Nat Rev Immunol, Blood, Frontiers, etc.) supporting T/NK lineage and state markers, exhaustion checkpoints, and NK receptor biology.